Cognitive function in Rett syndrome during trofinetide treatment
Part of Brain & nervous system, Genetic & congenital clinical trials.
This study looks at how trofinetide (a medicine for Rett syndrome) affects thinking and memory in people with Rett syndrome. It will follow participants who are starting this treatment through a specific clinic.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with Rett syndrome
- Starting trofinetide treatment through the Gillette Children's Rett syndrome clinic
- No loss of walking, hand use, or communication skills in the past 6 months
- Current medications have been stable for at least 4 weeks
- Not taking any other experimental drugs in the last 30 days
- No severe behavioral problems (like aggression or extreme hyperactivity) that would make it hard to participate
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug called NTI164 to see if it can safely help manage Rett syndrome symptoms in girls and young women. It is for those with classic Rett syndrome who have been stable recently and are not using certain other treatments.
This study tests whether fenfluramine, a medication already used for seizures, can help people with Rett syndrome. It aims to see if it improves daily life and reduces symptoms.
This Phase 2 trial studies whether an antioxidant “cocktail” helps children and teens with Rett syndrome compared with a placebo (inactive drink). If you join, you’ll get study assessments and blood tests to see if the treatment is safe and helpful.
This trial tests whether vorinostat is safe and helpful for girls and young women with Rett syndrome. Participants must have a confirmed MeCP2 mutation and be in a stable phase of the condition.
This trial tests an oral medication called NA-921 in females with Rett syndrome to see if it works better than a placebo. It may be an option for those who have a confirmed MECP2 gene mutation and stable seizure patterns.
This study measures brain and nerve activity (brain signals) to find patterns that match Rett syndrome. It may help researchers better track Rett changes over time and develop more precise ways to measure response in future treatments.
Hear when a new Rett Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.